Review: Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia

Proton pump inhibitors (PPIs) are the most widely used drugs for treatment of gastroesophageal reflux disease. However, approximately 20% of patients with reflux esophagitis and 40% of those with nonerosive reflux diseases complain of troublesome symptoms, even during treatment with PPIs. In patients with reflux esophagitis, dose escalation and co-administration with a histamine H2-receptor antagonist are potential approaches, since the major cause of PPI resistance is incomplete suppression of gastric acid secretion. On the other hand, for patients with nonerosive reflux disease, switching from PPIs to pain modulators is often necessary for improvement of symptoms, since 25% of patients with nonerosive reflux disease have symptoms not caused by gastroesophageal acid reflux. Therapeutic approaches for PPI-resistant patients with reflux esophagitis and nonerosive reflux diseases are considered according to pathogenesis.

[1]  M. Hongo,et al.  A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease , 2008, Journal of Gastroenterology.

[2]  T. Hershcovici,et al.  Functional heartburn vs. non‐erosive reflux disease: similarities and differences , 2008, Alimentary pharmacology & therapeutics.

[3]  W. Chey,et al.  The influence of co‐morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro‐oesophageal reflux disease , 2008, Alimentary pharmacology & therapeutics.

[4]  B. Naliboff,et al.  The effect of auditory stress on perception of intraesophageal acid in patients with gastroesophageal reflux disease. , 2008, Gastroenterology.

[5]  Q. Aziz,et al.  Visceral hypersensitivity in non-erosive reflux disease , 2007, Gut.

[6]  S. Quan,et al.  Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease. , 2007, Gastroenterology.

[7]  R. Holloway,et al.  Defective triggering of secondary peristalsis in patients with non‐erosive reflux disease , 2007, Journal of gastroenterology and hepatology.

[8]  D. Sifrim,et al.  Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus , 2007, Gut.

[9]  M. Hongo,et al.  Efficacy of rabeprazole on heartburn symptom resolution in patients with non‐erosive and erosive gastro‐oesophageal reflux disease: a multicenter study from Japan , 2007, Alimentary pharmacology & therapeutics.

[10]  N. Vakil,et al.  Review article: the role of surgery in gastro‐oesophageal reflux disease , 2007, Alimentary pharmacology & therapeutics.

[11]  V. Wong,et al.  Distinct clinical characteristics between patients with nonerosive reflux disease and those with reflux esophagitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  Y. Kinoshita,et al.  A comparative study of intragastric acidity during post‐breakfast and pre‐dinner administration of low‐dose proton pump inhibitors: a randomized three‐way crossover study , 2006, Alimentary pharmacology & therapeutics.

[13]  J. Dent,et al.  The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus , 2006, The American Journal of Gastroenterology.

[14]  K. Haruma,et al.  The pharmacodynamic effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan , 2006, Journal of Gastroenterology.

[15]  J. Inadomi,et al.  Sub‐optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro‐oesophageal reflux disease , 2006, Alimentary pharmacology & therapeutics.

[16]  A. Sonnenberg,et al.  The Long-Term Natural History of Gastroesophageal Reflux Disease , 2006, Journal of clinical gastroenterology.

[17]  Myung-Gyu Choi,et al.  The Effect of Mosapride on Esophageal Motility and Bolus Transit in Asymptomatic Volunteers , 2006, Journal of clinical gastroenterology.

[18]  B. Wong,et al.  Systematic review on epidemiology of gastroesophageal reflux disease in Asia. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  R. Knill-Jones,et al.  Upper gastrointestinal mucosal abnormalities and blood loss complicating low‐dose aspirin and antithrombotic therapy , 2006, Alimentary pharmacology & therapeutics.

[20]  J. Tack,et al.  Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double‐blind, placebo‐controlled study , 2006, Alimentary pharmacology & therapeutics.

[21]  R. Fass,et al.  Systematic review: proton‐pump inhibitor failure in gastro‐oesophageal reflux disease – where next? , 2005, Alimentary pharmacology & therapeutics.

[22]  K. Lauritsen,et al.  A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study , 2005, Alimentary pharmacology & therapeutics.

[23]  Y. Kinoshita,et al.  Prevalence of endoscopically negative and positive gastroesophageal reflux disease in the Japanese , 2005, Scandinavian journal of gastroenterology.

[24]  Y. Kinoshita,et al.  Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists , 2004, Alimentary pharmacology & therapeutics.

[25]  S. Ishihara,et al.  Administration of H2 receptor antagonist with proton pump inhibitor is effective for long-term control of refractory reflux esophagitis. , 2004, Journal of clinical gastroenterology.

[26]  J. Tack,et al.  Approaches to endoscopic‐negative reflux disease: part of the GERD spectrum or a unique acid‐related disorder? , 2004, Alimentary pharmacology & therapeutics.

[27]  C. Finizia,et al.  The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease , 2003, European journal of gastroenterology & hepatology.

[28]  M. A. Karim Rumi,et al.  Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens , 2003, Journal of Gastroenterology.

[29]  Y. Kinoshita,et al.  Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection , 2003, Journal of gastroenterology and hepatology.

[30]  T. Koike,et al.  The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism , 2003, Alimentary pharmacology & therapeutics.

[31]  D. Johnson,et al.  Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis , 2002, American Journal of Gastroenterology.

[32]  Y. Kinoshita,et al.  Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis , 2001, Journal of gastroenterology and hepatology.

[33]  S. Ishihara,et al.  Influence of Helicobacter pylori infection on the prevalence of reflux esophagitis in Japanese patients , 2001, Journal of gastroenterology and hepatology.

[34]  M. Onda,et al.  Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations , 2001, Journal of Gastroenterology.

[35]  S. Ishihara,et al.  CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole , 2000, Alimentary pharmacology & therapeutics.

[36]  D. Castell,et al.  Proton pump inhibitors: better acid suppression when taken before a meal than without a meal , 2000, Alimentary pharmacology & therapeutics.

[37]  Y. Kinoshita,et al.  Helicobacter pylori infection influences nocturnal gastric acid breakthrough , 2000, Alimentary pharmacology & therapeutics.

[38]  I. Wiklund,et al.  Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. , 2000, European journal of gastroenterology & hepatology.

[39]  Y. Horie,et al.  Interaction Between NSAIDs and Steroid in Rat Stomach , 2000, Digestive Diseases and Sciences.

[40]  S. Ishihara,et al.  Prevalence of non‐ulcer dyspepsia in the Japanese population , 1999, Journal of gastroenterology and hepatology.

[41]  O. Kawamura,et al.  Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings , 1999, Journal of Gastroenterology.

[42]  J. Galmiche,et al.  Functional esophageal disorders. , 1999, Gastroenterology.

[43]  M. Matsuura,et al.  Is a proton pump inhibitor necessary for the treatment of lower-grade reflux esophagitis? , 1999, Journal of Gastroenterology.

[44]  A. Blum,et al.  Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification , 1999, Gut.

[45]  J. Hunter,et al.  NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications harmful to the esophagus? , 1999, Journal of clinical gastroenterology.

[46]  O. Kawamura,et al.  Interobserver and intraobserver variation in endoscopic assessment of GERD using the "Los Angeles" classification. , 1999, Gastrointestinal endoscopy.

[47]  T Ishizaki,et al.  CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. , 1998, Clinical pharmacology and therapeutics.

[48]  V. Savarino,et al.  Effect of One-Month Treatment with Nonsteroidal Antiinflammatory Drugs (NSAIDs) on Gastric pH of Rheumatoid Arthritis Patients , 1998, Digestive Diseases and Sciences.

[49]  Ruth,et al.  The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro‐oesophageal reflux disease , 1998, Alimentary pharmacology & therapeutics.

[50]  L. Lundell,et al.  Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. , 1997, Scandinavian journal of gastroenterology.

[51]  T. Chiba,et al.  Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese , 1997, Gut.

[52]  J. Carson,et al.  Dilated intercellular spaces: a morphological feature of acid reflux--damaged human esophageal epithelium. , 1996, Gastroenterology.

[53]  M. Aldersley,et al.  Patterns of acid reflux in complicated oesophagitis. , 1987, Gut.

[54]  D. De Wolf,et al.  Influence of xanthines on gastroesophageal reflux in infants at risk for sudden infant death syndrome. , 1986, Pediatrics.

[55]  R. Buice,et al.  Nifedipine: a potent inhibitor of contractions in the body of the human esophagus. Studies in healthy volunteers and patients with the nutcracker esophagus. , 1985 .

[56]  T. Ekström,et al.  Influence of theophylline on gastro-oesophageal reflux and asthma , 2004, European Journal of Clinical Pharmacology.

[57]  N. Vakil,et al.  Clinical effectiveness of laparoscopic fundoplication in a U.S. community. , 2003, The American journal of medicine.

[58]  Ebra,et al.  ESOPHAGITIS ASSOCIATED WITH THE USE OF ALENDRONATE , 2000 .